Display options
Cite
Danesh A, Ljungh Å, Mattiasson B, et al. Synergistic effect of haloduracin and chloramphenicol against clinically important Gram-positive bacteria. Biotechnol Rep (Amst). 2016;13:37-41doi: 10.1016/j.btre.2016.12.008.
Danesh, A., Ljungh, �. �., Mattiasson, B., & Mamo, G. (2017). Synergistic effect of haloduracin and chloramphenicol against clinically important Gram-positive bacteria. Biotechnology reports (Amsterdam, Netherlands), 1337-41. https://doi.org/10.1016/j.btre.2016.12.008
Danesh, Abolghasem, et al. "Synergistic effect of haloduracin and chloramphenicol against clinically important Gram-positive bacteria." Biotechnology reports (Amsterdam, Netherlands) vol. 13 (2017): 37-41. doi: https://doi.org/10.1016/j.btre.2016.12.008
Danesh A, Ljungh Å, Mattiasson B, Mamo G. Synergistic effect of haloduracin and chloramphenicol against clinically important Gram-positive bacteria. Biotechnol Rep (Amst). 2016 Dec 27;13:37-41. doi: 10.1016/j.btre.2016.12.008. eCollection 2017 Mar. PMID: 28352561; PMCID: PMC5361133.
Copy Download .nbib Format: NLM
Share it on

Biotechnol Rep (Amst). 2016 Dec 27;13:37-41. doi: 10.1016/j.btre.2016.12.008. eCollection 2017 Mar.

Synergistic effect of haloduracin and chloramphenicol against clinically important Gram-positive bacteria.

Biotechnology reports (Amsterdam, Netherlands)

Abolghasem Danesh, Åsa Ljungh, Bo Mattiasson, Gashaw Mamo

Affiliations

  1. Department of Biotechnology, Lund University, P.O. Box 124, 221 00, Lund, Sweden; Biotechnology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  2. Department of Medical Microbiology, Lund University, SE-223 62 Lund, Sweden.
  3. Department of Biotechnology, Lund University, P.O. Box 124, 221 00, Lund, Sweden.

PMID: 28352561 PMCID: PMC5361133 DOI: 10.1016/j.btre.2016.12.008

Abstract

The emergence of drug-resistant pathogens has triggered the search for more efficient antimicrobial agents and formulations for treatment of infections. In recent years, combination therapy has become one of the effective clinical practices in treating infections. The present study deals with the effect of haloduracin, a lantibiotic bateriocin and chloramphenicol against clinically important bacteria. The combined use of haloduracin and chloramphenicol resulted in remarkable synergy against a spectrum of microorganisms including strains of

Keywords: Chloramphenicol; Combination therapy; Drug resistance; Haloduracin; Topical antibiotics

References

  1. J Appl Microbiol. 2012 Apr;112(4):831-40 - PubMed
  2. Lancet. 2006 Sep 2;368(9538):874-85 - PubMed
  3. Allergy. 1996 Jan;51(1):67-9 - PubMed
  4. Acta Otorhinolaryngol Ital. 2007 Feb;27(1):27-32 - PubMed
  5. Nat Chem Biol. 2011 Jun;7(6):348-50 - PubMed
  6. Nat Rev Microbiol. 2009 Sep;7(9):629-41 - PubMed
  7. J Antimicrob Chemother. 2007 Jun;59(6):1271-9 - PubMed
  8. BMJ. 2009 Jun 12;338:b1699 - PubMed
  9. Contact Dermatitis. 2008 Jan;58(1):32-6 - PubMed
  10. Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17243-8 - PubMed
  11. J Appl Microbiol. 2012 Oct;113(4):723-36 - PubMed
  12. Nat Rev Microbiol. 2013 Feb;11(2):95-105 - PubMed
  13. Ann R Coll Surg Engl. 2013 Jan;95(1):e20-1 - PubMed
  14. JRSM Short Rep. 2013 Mar;4(3):20 - PubMed
  15. J Antimicrob Chemother. 1998 Aug;42(2):277-8 - PubMed
  16. J Infect. 2009 Sep;59 Suppl 1:S4-16 - PubMed
  17. Antimicrob Resist Infect Control. 2014 May 21;3:16 - PubMed
  18. Clin Microbiol Rev. 1990 Jan;3(1):46-65 - PubMed
  19. J Antimicrob Chemother. 1999 May;43(5):699-702 - PubMed
  20. Rev Infect Dis. 1981 May-Jun;3(3):479-91 - PubMed
  21. N Engl J Med. 2006 Aug 17;355(7):666-74 - PubMed
  22. ACS Chem Biol. 2009 Oct 16;4(10):865-74 - PubMed
  23. Biotechnol Lett. 2011 Jul;33(7):1339-44 - PubMed
  24. FEMS Microbiol Rev. 2004 Nov;28(5):519-42 - PubMed

Publication Types